Skip to main content
. 2014 Jul 15;190(2):208–217. doi: 10.1164/rccm.201403-0446OC

Figure 2.

Figure 2.

Proportion of patients with a change in pulmonary vascular resistance index of 20% from baseline. After 16 weeks, there was no difference in the percentage of patients who achieved a greater than or equal to 20% reduction in pulmonary vascular resistance index between the bosentan- and placebo-treated groups.